On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25810313.
- Also identified by DOI 10.1126/scitranslmed.3010274.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.
Medical subject headings
- Immune Tolerance
- Lymphocyte Activation
- Neoplasms
- T-Lymphocytes